Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032285 (pneumonia)
 54,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The combined use of microbiological, serological and clinical laboratory methods was evaluated for etiological diagnosis of pneumonia in 106 military conscripts. Special attention was paid to rapid diagnosis of pneumococcal pneumonia and its differentiation from viral and mycoplasmal pneumonia. The microbial etiology could be established in 91 (86%) of the pneumonia patients. Pneumococcal etiology was definitely established in 32 (30%) patients and considered probable in an additional 21 patients (20%). Infection with Mycoplasma pneumoniae and adenovirus was confirmed in 23 (22%) of the patients. Mixed infections was observed in 28 (31%) of the patients with established etiology. Detection of pneumococcal antigen was the best rapid diagnostic method, being positive in 90% of the patients with purulent sputum samples in the group with a definite diagnosis of pneumococcal pneumonia prior to the start of antimicrobial treatment, while Gram stain was positive in only 65% of these patients. Sputum purulence could be used to differentiate very significantly pneumococcal from viral and mycoplasmal pneumonia (p less than 0.001). These categories of pneumonia could also be successfully differentiated by clinical laboratory tests, of which the white blood cell count and C-reactive protein were most useful. The suggested cut-off value for the cell count was 10 X 10(9)/l, and for C-reactive protein 85 mg/l. These tests could not differentiate viral from mycoplasmal pneumonias.
 ...
PMID:Etiological diagnosis of pneumonia in military conscripts by combined use of bacterial culture and serological methods. 313 34

Mycoplasma pneumoniae, which usually causes mild infections in normal children, has been shown to cause isolated cases of severe pneumonia in children with sickle cell disease. We recently observed an outbreak of Mycoplasma pneumonia in three sisters with homozygous sickle cell disease. Two of them required hospitalization, and one progressed to respiratory failure requiring prolonged ventilatory assistance. All eventually recovered without long-term pulmonary complications. Familial outbreaks are not uncommon in Mycoplasma infection, but they have not been described previously in siblings with sickle cell disease. It is assumed that local or systemic host defense abnormalities predispose patients with sickling syndromes to more severe courses of Mycoplasma infections.
 ...
PMID:Severe Mycoplasma pneumonia in three sisters with sickle cell disease. 315 38

During 3 trials, using affected pigs of various ages, tiamulin was evaluated for treatment of experimentally induced mycoplasmal pneumonia. Pneumonia was induced in respiratory tract disease-free swine by intratracheal inoculation of a lung homogenate containing Mycoplasma hyopneumoniae. Eleven days after inoculation, when more than 20% of pigs were coughing, pigs were allotted to 3 or 4 groups (n = 8 pigs each) and were given regimens of no medication or 60 mg, 120 mg, or 180 mg of tiamulin/L of drinking water for 10 days. Twenty-one days after cessation of medication, pigs were euthanatized and then were necropsied. Results obtained from the 3 trials did not indicate significant difference among treatment groups in severity of macroscopic or microscopic lesions induced by M hyopneumoniae or in detection of M hyopneumoniae by use of immunofluorescent technique. Clinical evaluations, daily gain, and feed efficiency did not differ significantly among treatment groups. In this study, tiamulin administration did not have beneficial effects in swine with mycoplasmal pneumonia.
 ...
PMID:Evaluation of tiamulin for treatment of mycoplasmal pneumonia in swine. 317 Mar 19

Laboratory and clinical studies on rokitamycin (RKM) dry syrup, a new macrolide antibiotic, were carried out in the field of pediatrics. The results are summarized as follows. 1. Plasma concentrations and urinary recovery rates after oral administration on fasting of RKM dry syrup at doses of 10 mg/kg and 20 mg/kg to 2 and 1 cases, respectively, were determined. Peak plasma levels were obtained in 30 minutes after administration of both dosages with half-lives of 1.5 to 2.2 hours. A clear-cut dose response was observed. Urinary recovery rates in the first 6 hours after administration ranged from 1.75 to 2.26%. 2. The MICs of RKM against 80 clinical isolates (Streptococcus pyogenes 9, Streptococcus pneumoniae 14, Branhamella catarrhalis 4, Haemophilus influenzae 27, Haemophilus parainfluenzae 9, Haemophilus haemolyticus 2, Haemophilus parahaemolyticus 14 and Campylobacter jejuni 1) were compared with MICs of midecamycin acetate (MOM), josamycin (JM) and erythromycin (EM). The antibacterial activity of RKM was superior to those of MOM and JM and slightly inferior to that of EM. 3. Twenty-eight pediatric patients with acute infectious diseases (acute tonsillitis 4, streptococcal infection 4, acute bronchitis 9, pneumonia 4, mycoplasmal pneumonia 2 and Campylobacter enteritis 5) were treated with RKM dry syrup at a daily dose of 12-42.9 mg/kg t.i.d. as a rule. Efficacy rates were 92.9% clinically and 58.6% bacteriologically. 4. No adverse reactions were observed. Abnormal laboratory findings were mild; thrombocytosis in 2 and eosinophilia in 1. 5. The taste and the odor of RKM dry syrup preparation were sufficiently tolerable for the pediatric patients to accept it.
 ...
PMID:[Laboratory and clinical studies of rokitamycin dry syrup in the field of pediatrics]. 317 61

The major findings and conclusions of the present study are: 1. Evidence of the etiology of the pneumonia was established in 86% of 106 young men with pneumonia. Pneumococcus was the most common etiologic agent; it was detected definitely in 30% of the pneumonia patients, and possibly in another 20%, by blood culture, sputum culture, antigen detection, and serological methods. 2. Pneumococcal antigen detection from purulent pretreatment sputum samples was the best rapid diagnostic method for pneumococcus; it was capable of identifying 90% of the pneumococcal pneumonias definite by our criteria, whereas sputum Gram stain was positive in 65% of these. 3. Detection of adenoviral antigens from nasopharyngeal specimens (NPS) by EIA or IF method or adenovirus DNA by HYB method showed good specificity but a somewhat lower sensitivity than did adenovirus isolation from NPS. 4. Adenovirus antigens and DNA can be demonstrated also from sputum specimens. 5. EIA is slightly superior to the CF method in detecting antibody responses to adenovirus, but the detection of different antibody classes offers no additional diagnostic possibilities. 6. Isolation of Mycoplasma pneumoniae from bronchoalveolar fluid in pneumonia patients is a specific and sensitive method in the diagnosis of mycoplasmal pneumonia. 7. It seems possible to differentiate by clinical signs and symptoms and by high CRP (over 85mg/1) and WBC (over 10 x 10(9)/1) values pneumococcal pneumonias from viral, mycoplasmal and mixed pneumonias and from upper respiratory infections. Moderately elevated CRP values were observed in adenoviral (Mean 50 mg/1) and in mycoplasma (mean 59 mg/l) pneumonias, as well as in MRI (mean 44 mg/l).
 ...
PMID:Rapid etiological diagnosis of pneumonia in young men. 318 95

In a study of rokitamycin (RKM) dry syrup for its usefulness in pediatric infections, the following results were obtained: 1. Frequencies of RKM-resistant strains among fresh isolates from sick children were very low, and 4.4% of 68 isolates of Staphylococcus aureus, 4.2% of 48 isolates of Streptococcus pneumoniae, and none of 96 isolates of Streptococcus pyogenes were found to be RKM-resistant. 2. Hypo- to achlorhydria was found in 2 (3.77%) of 53 children. 3. When children were administered once orally with 5, 10 and 15 mg/kg of RKM dry syrup at fasting, mean peak values of plasma concentration were 0.25, 0.55 and 0.74 micrograms/ml with a T1/2 (beta) of 2.18, 1.97 and 2.00 hours, respectively. Urinary recovery rates during the first 0-6 hours were quite low, and values were 1.21, 1.38 and 2.23%, respectively. 4. The clinical efficacy of RKM dry syrup was studied on children chiefly with acute pneumonia, mycoplasmal pneumonia and tonsillitis. Among 379 children from whom pathogens had been determined, responses to the treatment were excellent in 186, good in 144, fair in 24, poor in 20 and unknown in 5 patients, the overall efficacy rate being 88.2%. Among all 598 treated patients, including those with undetermined pathogens, responses were excellent in 247, good in 269, fair in 42, poor in 35 and unknown in 5 patients, the efficacy rate being 87.0%. 5. The clinical efficacy of the drug in treating Chlamydia infection in 12 patients including a Chlamydia carrier and the clinical efficacy in treating Campylobacter enteritis in 36 patients were studied. All the cases showed "good" responses. Among 66 patients with mycoplasmal pneumonia, responses were excellent in 33 and good in 27 patients, with an efficacy rate of 90.9%. 6. The optimal dose of RKM dry syrup seemed to be in the range between 20 and 40 mg/kg. It appeared, however, that a dose of about 40 mg/kg would be required to eradicate the pathogen from the pharynx in S. pyogenes infection. 7. Adverse reactions to RKM dry syrup were found in 9 (1.45%) of 622 patients. The reactions were gastrointestinal symptoms except eruption occurred in 1 patient, but they were all mild. Laboratory examinations revealed eosinophilia in 19 and abnormal hepatic enzyme activities in 8 of 455 patients studied, but such abnormalities were all transient and mild.
 ...
PMID:[Appraisal of rokitamycin in the pediatric field]. 322 30

Clinical efficacies of a new macrolide antibiotic, rokitamycin (RKM, TMS-19-Q), were studied in acute pediatric infections. Responses to the RKM administration were evaluable in 62 out of 68 patients consisted of 7 patients with pharyngitis (efficacy rate of 85.7%, 6/7 patients), 4 with bronchitis (25.0%, 1/4), 9 with tonsillitis (100%, 9/9), 13 with mycoplasmal pneumonia (100%, 13/13), 13 with hemolytic streptococcal infections (92.3%, 12/13), 14 with pneumonia (57.1%, 8/14), one with pertussis (100%, 1/1) and another with Chlamydia pneumonia (100%, 1/1) thus an overall efficacy rate of 82.3% was achieved. Urticaria was observed in one of the patients as an adverse reaction to the drug, while abnormal laboratory test results were noted in 3 patients, but none of such changes were severe. The drug, even when administered in combination with a theophylline preparation, exerted no effects on the serum concentration of the latter.
 ...
PMID:[Clinical results of a rokitamycin dry syrup in pediatric infections]. 322 32

Rokitamycin dry syrup (RKM), a new macrolide antibiotic preparation, was evaluated for its safety, efficacy and pharmacokinetics in 19 children. RKM was effective in mycoplasmal pneumonia, Chlamydia trachomatis pneumonitis and Campylobacter gastroenteritis. Efficacies of RKM in streptococcal pharyngitis and Haemophilus influenzae pneumonia, however, were insufficient. Pharmacokinetic observations seemed to indicate that RKM achieved higher blood concentrations than older macrolides, but a large individual variation was observed. Diarrhea which was the only type of side effect observed in our cases, was encountered in 2 of 17 evaluable cases. From these data, RKM seems to have a place in the treatment of pediatric infectious diseases.
 ...
PMID:[Clinical and pharmacokinetic studies of rokitamycin in children]. 322 33

279 patients with 285 episodes of bacteremic pneumococcal pneumonia (Pnb), treated at the 2 departments for infectious diseases in Stockholm, Sweden, were reviewed retrospectively. Almost half of all episodes were caused by serotypes 3, 9 and 4 (in that order). The overall mortality rate was 7% and as low as 5% if patients with extrapulmonary complications were excluded. As in other studies male sex, alcoholism and absence of leukocytosis on admission to hospital were all associated with a higher mortality rate. However, the prognosis for old patients was much better than in most other studies. This was true also when the infecting strain was of serotype 3. For 89 consecutive patients out of the 279 ones with Pnb the clinical, laboratory and chest X-ray data were compared with those of 44 patients with non-bacteremic pneumococcal pneumonia (Pn) and 27 patients with Mycoplasma pneumoniae pneumonia (MP). Within the pneumococcal group almost all non-bacteremic patients had respiratory tract symptoms compared to less than half of the patients with bacteremic disease. High age, alcoholism, chills, pleuritic chest pain, a leukocyte count of greater than 15 x 10(9)l and an elevated CRP were factors significantly more common among those with pneumococcal pneumonia than among the MP patients. On chest X-ray an alveolar pattern was seen in all but 2 of the totally 133 patients with a pneumococcal pneumonia, but also in half the patients with MP.
 ...
PMID:Bacteremic pneumococcal pneumonia in Sweden: clinical course and outcome and comparison with non-bacteremic pneumococcal and mycoplasmal pneumonias. 339 36

Flomoxef (FMOX, 6315-S), a new parenteral oxacephem antibiotic, was studied bacteriologically and clinically. 1. The MIC and MBC values of FMOX and cefuzonam (CZON) were determined against strains of Staphylococcus aureus recently isolated from clinical materials. In MICs against methicillin- and cefazolin (CEZ)-sensitive strains, FMOX and CZON were almost equivalent. In MBC, FMOX showed lower values than CZON. Against resistant strains, both MIC and MBC values indicated that FMOX was superior to CZON, and particularly, values showed large differences in MBC. 2. FMOX was administered intravenously at doses of 20.0-35.1 mg/kg 3 or 4 times daily to 17 children aged 2 months to 8 years. The therapeutic effect was determined in 16 cases (pneumonia 9 cases, pyothorax 1, urinary tract infection 2, staphylococcal scalded skin syndrome 1, cellulitis 2 and arthritis 1). One remaining case was unevaluable and later found to be mycoplasmal pneumonia. The effect was determined as excellent in 10 cases and good in 6 cases. All the causative organisms detected in these evaluable cases were eliminated. 3. There were no symptoms or findings that suggested the occurrence of side effects of the drug in any of the 17 cases. With regard to laboratory values, a slight elevation of GPT was found in 1 case only. 4. In a case with pyothorax, the concentration of the drug in the pleural fluid determined on the day following the initiation of treatment was 18.2 micrograms/ml at 30 minutes after intravenous injection of the drug at 33 mg/kg. The concentration was 46.7 times as high as the MIC (0.39 micrograms/ml) against the causative organism S. aureus. 5. Two doses of FMOX were intravenously administered at the dose of 50 mg/kg to a female infant ventriculoperitoneal shunt infection which had been treated with other drugs. In this case showing relatively low cell counts of 171-240/mm3 in the ventricular fluid, concentrations of the drug measured by HPLC were as low as 0.53 and 0.98 micrograms/ml 1 hour after intravenous injection of the drug. 6. The above results suggested that FMOX is a new antibiotic drug easy to use and effective for the treatment of general infections in children.
 ...
PMID:[Bacteriological and clinical studies of flomoxef in the pediatric field]. 343 Jul 20


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>